TINA MITTERLING: Open Payments
NPI 1427242239 · SAN DIEGO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$807 in 19 payments from 9 companies in 2025. Trend: 2023 $105 · 2024 $0 · 2025 $807
Food & beverage: $807
| Company | Payments | Amount |
|---|---|---|
| Phathom Pharmaceuticals, Inc. | 2 | $223 |
| Novo Nordisk Inc | 4 | $202 |
| Lilly USA, LLC | 5 | $172 |
| ABBVIE INC. | 3 | $130 |
| Novartis Pharmaceuticals Corporation | 1 | $19 |
| GlaxoSmithKline, LLC. | 1 | $18 |
| AstraZeneca Pharmaceuticals LP | 1 | $15 |
| Amgen Inc. | 1 | $15 |
| Exact Sciences Corporation | 1 | $14 |
Products named: VOQUEZNA, MOUNJARO, Ozempic, VRAYLAR, Wegovy, LEQVIO, SHINGRIX, FARXIGA.
Industry payments across CA — which companies pay providers there.
